Lung cancer study finds younger patients have more targetable mutations

An international study has found that younger adults diagnosed with non-small cell lung cancer (NSCLC) are significantly more likely to possess targetable genetic mutations than older patients. Analyzing genomic and immune data from 14,246 patients, researchers discovered that nearly 58% of younger patients exhibit actionable genetic mutations, compared to approximately 45% of those aged 55 and older.

Younger patients frequently demonstrate specific molecular drivers such as ALK, ROS1, and EGFR, which can guide targeted therapy decisions. In contrast, older patients more commonly present with KRAS-related changes and a higher overall tumor mutational burden. The study also identified age-related differences in immune markers, including LAG3 and TIGIT, which are being investigated as potential targets for future immunotherapy.

The research, led by investigators from the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine in collaboration with Labcorp and the Dana-Farber Cancer Institute, suggests that age is a critical variable in understanding tumor biology. These findings support the need for age-stratified diagnostic protocols and comprehensive genomic profiling to facilitate personalized treatment plans.